EVMN
Evommune, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Evommune, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Evommune has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceIn June 2024, we entered into a license agreement with AprilBio (the "AprilBio License Agreement") under which AprilBio granted us an exclusive worldwide license to develop and commercialize EVO301.
EVMN 10-Kaccession 0001193125-26-093932
SentenceReport of Independent Registered Public Accounting Firm (BDO USA, P.C.; New York, NY; PCAOB ID# 243 )
EVMN 10-Kaccession 0001193125-26-093932
SentenceIn December 2020, we entered into a License, Development and Commercialization Agreement with Dermira, pursuant to which Dermira granted us an exclusive, worldwide license to develop and commercialize certain compounds, including the compound in development by us known as EVO756 (the "Dermira License Agreement").
EVMN 10-Kaccession 0001193125-26-093932
SentenceLease Agreement, dated June 29, 2025, by and between the Registrant and Hudson Page Mill Hill, LLC
EVMN 10-Kaccession 0001193125-26-093932
SentenceIn March 2024, we entered into a second strategic collaboration with Maruho (the "Maruho Greater Asia Agreement") and granted Maruho the exclusive license to develop and commercialize EVO756 in Greater China and certain other Asian countries.
EVMN 10-Kaccession 0001193125-26-093932
Evommune, Inc.
6.72
Largest filed tie
—
Expected move
No implied move.